# An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma

> **NCT03580564** · PHASE2 · COMPLETED · sponsor: **Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.** · enrollment: 109 (actual)

## Conditions studied

- Classical Hodgkin Lymphoma

## Interventions

- **DRUG:** KL-A167

## Key facts

- **NCT ID:** NCT03580564
- **Lead sponsor:** Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-01
- **Primary completion:** 2020-08-22
- **Final completion:** 2022-01-13
- **Target enrollment:** 109 (ACTUAL)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03580564

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03580564, "An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03580564. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*